Statistical methods in immunology & rheumatology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
ANCOVA
Odds ratio
Multiple imputation / missing data
Cochran-Mantel-Haenszel test
Mixed-effects model
Logistic regression
Kaplan-Meier estimation
Time-to-event endpoints
All immunology & rheumatology trials
4 results
- CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.
- CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.
- CLARITYIndependent statistical analysis of the phase 3 CLARITY trial of oral cladribine in relapsing-remitting multiple sclerosis, including randomized design, annualized qualifying relapse rate, relative risks, confidence intervals, chi-squared testing, intention-to-treat analysis, and…
- SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…